V8 Peptides — Engineered Performance
Research Library
Semaglutide Half-Life Math: Pharmacokinetics vs Stability
SemaglutideReconstitution & Handling

Semaglutide Half-Life Math: Pharmacokinetics vs Stability

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

How long does semaglutide last in published animal work, and how is half-life used in planning? The discovery paper reported a plasma half-life of 46.1 h in mini-pigs after intravenous administration and a mean residence time of 63.6 h after subcutaneous administration. Half-life arithmetic is simple: the fraction remaining after time t is 0.5^(t ÷ t½), so with 46.1 h, about 70% remains at 24 h and about 8% at 168 h. Those numbers describe a mini-pig study, not a laboratory solution, and shelf life of a prepared stock is a separate stability question. This article keeps the two apart and shows the formulas. V8 Peptides supplies a 10 mg lyophilized semaglutide vial, for laboratory research use only.

"Half-life" appears in two different conversations about semaglutide. In pharmacokinetics it describes how fast the compound disappears from plasma in a living animal. In storage and stability it describes, loosely, how long a prepared solution stays usable. They have nothing to do with each other numerically, and confusing them is a common error in lab notebooks. This article separates them, gives the formula-only arithmetic for the first, and summarizes the stability literature for the second. See also semaglutide storage and stability and the semaglutide research guide. For laboratory research use only.

Why semaglutide persists: the design

Native GLP-1 is cleared within minutes. The semaglutide design paper set out to produce a once-weekly analog by increasing albumin affinity and securing stability against metabolic degradation; the fatty acid moiety and linking chemistry were the key features, and the molecule carries two amino-acid substitutions (Aib at position 8 and Arg at 34) and a derivatization at lysine 26 (reference 1). Earlier structure-activity work on the related liraglutide series found that fatty-acid length is the most important parameter for protraction in vivo (reference 2). The product page summarizes the same features: Aib at position 8 resists cleavage by DPP-4 and a C18 fatty diacid on lysine 26 drives reversible albumin binding.

Reported quantityValueSpecies and routeSource
Plasma half-life46.1 hMini-pig, intravenousReference 1
Mean residence time63.6 hMini-pig, subcutaneousReference 1
Intact parent in plasma69–83% of drug-related materialHuman, rat, monkeyReference 3
Intact parent in urine3.1% (human), under 1% (rat), not detected (monkey)Human, rat, monkeyReference 3

The arithmetic of half-life

For first-order elimination, the rate constant is k = ln 2 ÷ t½. With t½ = 46.1 h, k = 0.693 ÷ 46.1 = 0.0150 per hour. The fraction of the starting amount remaining after time t is e^(−kt), which equals 0.5^(t ÷ t½). The table applies this to the mini-pig value as an illustration.

Time after peakHoursFraction remaining (t½ = 46.1 h)
1 day240.70
2 days480.49
3 days720.34
7 days1680.080
14 days3360.0064

After n half-lives the fraction eliminated is 1 − 0.5^n: 50% after one, 87.5% after three, 96.9% after five, which at 46.1 h is about 9.6 days for the five. Accumulation with repeated administration at interval τ follows R = 1 ÷ (1 − e^(−kτ)); for τ = 168 h and the same k, R = 1.087, meaning that the steady-state peak is only about 9% above the first. These are illustrations of the formulas applied to one published value. They assume one-compartment first-order kinetics and ignore absorption, so real profiles differ, and they say nothing about any use outside the laboratory.

Why half-life does not transfer between species

A pharmacokinetic analysis of peptide drugs derived algebraic equations for clearance, volume of distribution and half-life and examined how they scale across species, covering unconjugated peptides and fatty-acid-conjugated ones including semaglutide (reference 4). The practical message is that elimination half-life results from clearance and volume together, and both scale differently with body size; a mini-pig half-life cannot be multiplied or divided to give a mouse half-life. If a study design needs exposure over time in a particular strain, it should be measured there, with plasma sampled across at least several half-lives and the parent compound quantified separately from metabolites.

The absorption, metabolism and excretion work supports that last point. Semaglutide was metabolized by proteolytic cleavage of the peptide backbone and sequential beta-oxidation of the fatty acid sidechain, metabolism was not confined to specific organs, and urine was the primary excretion route in humans and animals (reference 3). A method that reports total radioactivity or a nonspecific immunoassay would overstate parent compound.

Route matters: absorption papers

Route changes the shape of the exposure curve even when elimination is unchanged. The mini-pig MRT after subcutaneous administration (63.6 h) is longer than the intravenous half-life (46.1 h) because MRT includes absorption time (reference 1). A separate study of an oral semaglutide formulation in clinical and dog studies found that absorption took place in the stomach, near the tablet surface, and required coformulation with an absorption enhancer that protected against enzymatic degradation through local buffering (reference 5). That work concerns a formulation with an enhancer and does not apply to dissolving research powder; it is cited to show that absorption and elimination are separate parts of an exposure profile.

Half-life is not shelf life

A prepared research solution has no pharmacokinetic half-life. What matters is chemical and physical stability in the vial. A solution-state study using LC-HRMS reported thirteen degradation impurities under thermal stress at 25 °C and 40 °C and identified pH as a key factor, with some impurities appearing when water was the solvent (reference 6). It does not provide a shelf life for a refrigerated reconstituted vial. Forced-degradation approaches for peptides and proteins are reviewed in the pharmaceutical literature (reference 7).

QuestionConceptWhere the answer comes from
How fast does it leave plasma?Pharmacokinetic half-lifeAnimal sampling, species-specific
How long is a stock usable?Solution stabilityHPLC or LC-MS time series on the stock
How long does the dry vial keep?Storage stabilityManufacturer data, storage conditions
Is binding to albumin changing the free fraction?Protein bindingBinding assay with and without albumin

The product page states 2–8 °C for short-term storage, −20 °C for long-term holding, and protection from heat, moisture and light. For a prepared stock, the practical rule is to label date and concentration, keep it cold, divide frozen stock into single-use portions and verify with HPLC if a result depends on exact concentration. How long reconstituted peptides last, storing research peptides and semaglutide reconstitution and handling give the handling detail.

A stock-stability check you can run

  1. Prepare one stock at a known concentration, C = m ÷ V (the reconstitution calculator converts units).
  2. Divide into identical aliquots in low-binding tubes; store at the intended conditions.
  3. Analyze one aliquot at time zero by HPLC, recording main-peak area and total area.
  4. Analyze further aliquots at pre-set times, such as 1, 3, 7 and 14 days.
  5. Plot main-peak area percent and absolute area against time. If the absolute area falls without new peaks, suspect adsorption or precipitation instead of degradation.
  6. Report the time at which any pre-specified limit (for example 5% loss) was crossed, with the conditions.

The same design applies with mass spectrometry for identification of new peaks; see semaglutide purity testing and understanding HPLC purity, and lot data on the COA page. For sourcing see where to buy semaglutide, and the shop for the catalog.

Sampling design for a half-life measurement

If a project needs its own half-life, the sampling schedule determines whether the estimate is trustworthy. The terminal slope of a log-concentration plot must be fitted over at least three half-lives of data, so a compound with a half-life near two days needs sampling out to roughly a week or more. Early time points define distribution; late time points define elimination; a sparse schedule that misses either gives a biased value. Quantification should use a method specific for the parent compound, such as LC-MS with an internal standard, and should state the lower limit of quantification, because values near that limit flatten the terminal slope artificially. Report the number of animals per time point, the sampling matrix (plasma or serum), the anticoagulant, the handling time between draw and freezing, and the fitting model. Peptides that adsorb to tubes or are cleaved by plasma enzymes after collection can look as if they disappear faster than they do, so samples should be kept cold and processed with a documented, uniform interval. These design points are general pharmacokinetic practice, and the cited abstracts do not describe such details, so none are attributed to them.

What can and cannot be concluded

From the abstracts cited here one can say that semaglutide's engineered albumin binding and Aib substitution are associated with a plasma half-life of 46.1 h in mini-pigs and that metabolism is proteolytic and by beta-oxidation across the species studied. One cannot say how long a laboratory solution stays intact, and one should not apply a mini-pig number to another species. A notebook entry should say which half-life it means. All material discussed is for laboratory research use only.

Frequently asked questions

What half-life was reported for semaglutide in animals?

The discovery paper reported a plasma half-life of 46.1 h in mini-pigs after intravenous administration and a mean residence time of 63.6 h after subcutaneous administration.

How is the fraction remaining calculated?

0.5 raised to the power t divided by the half-life. With 46.1 h, about 70% remains at 24 h and about 8% at 168 h.

Does the mini-pig half-life apply to mice or rats?

No. Clearance and volume of distribution scale differently across species, so half-life must be measured in the species of interest.

Is half-life the same as shelf life?

No. Half-life describes elimination from plasma in an animal. Shelf life is the time a solution or vial stays within specification.

How is semaglutide metabolized in animals?

By proteolytic cleavage of the peptide backbone and sequential beta-oxidation of the fatty acid sidechain, not confined to specific organs.

What did the degradation study find?

Thirteen impurities under solution-state thermal stress, with pH a key factor. The study used elevated temperatures and does not set a shelf life for a refrigerated stock.

How should the vial be stored?

Per the product page: 2–8 °C, −20 °C for long-term holding, and protection from heat, moisture and light.

How can I check my own stock's stability?

Aliquot, store, and analyze by HPLC at pre-set times, tracking main-peak area percent and absolute area against time.

How is stock concentration calculated?

Vial mass in mg divided by diluent volume in mL. The calculator handles unit conversions.

Is this article a statement about use outside the laboratory?

No. It explains formulas and summarizes published animal studies. Semaglutide is supplied for laboratory research use only.

Related reading: Semaglutide and Insulin: Islet Research Readouts, Semaglutide Appetite Research: Brain Access to Circuits, Semaglutide Purity Testing: HPLC, Mass and Content Math.

References

  1. Lau J, Bloch P, Schäffer L, Pettersson I, Spetzler J, Kofoed J, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. 2015;58(18):7370-80. doi:10.1021/acs.jmedchem.5b00726
  2. Madsen K, Knudsen LB, Agersoe H, Nielsen PF, Thøgersen H, Wilken M, et al. Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness. J Med Chem. 2007;50(24):6126-32. doi:10.1021/jm070861j
  3. Jensen L, Helleberg H, Roffel A, van Lier JJ, Bjørnsdottir I, Pedersen PJ, et al. Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species. Eur J Pharm Sci. 2017;104:31-41. doi:10.1016/j.ejps.2017.03.020
  4. Nordell P, Jansson-Löfmark R, Gennemark P. Systemic Pharmacokinetic Principles of Therapeutic Peptides. Clin Pharmacokinet. 2026;65(4):571-582. doi:10.1007/s40262-025-01615-z
  5. Buckley ST, Bækdal TA, Vegge A, Maarbjerg SJ, Pyke C, Ahnfelt-Rønne J, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med. 2018;10(467). doi:10.1126/scitranslmed.aar7047
  6. Malgave A, Akbar S, Joseph A, Dande Aishwarya, Peraman R, Malayandi R. Effect of pH, buffers, molarity, and temperature on solution state degradation of semaglutide using LC-HRMS: A preformulation protocol for peptide drug delivery. Eur J Pharm Biopharm. 2025;214:114780. doi:10.1016/j.ejpb.2025.114780
  7. Hawe A, Wiggenhorn M, van de Weert M, Garbe JH, Mahler HC, Jiskoot W. Forced degradation of therapeutic proteins. J Pharm Sci. 2012;101(3):895-913. doi:10.1002/jps.22812
  8. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-75. doi:10.1007/s11095-009-0045-6

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.